Bicara Therapeutics
BCAX
69 hedge funds and large institutions have $928M invested in Bicara Therapeutics in 2024 Q3 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
66.96% more ownership
Funds ownership: 0% → 66.96% (+67%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$177M |
| 2 |
TGA
TPG GP A
Fort Worth,
Texas
|
+$76.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$58M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$56.2M |
| 5 |
DM
Deerfield Management
New York
|
+$45.8M |
Top Sellers
BCAX Hedge Fund Activity: Q3 2024 in Review
69 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Bicara Therapeutics (BCAX) for Q3 2024, worth a combined $928M.
Buyers outnumbered sellers: 69 funds opened new BCAX positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $177M.
- 69 institutional investors held Bicara Therapeutics (BCAX) as of Q3 2024, up from 0 in Q2 2024.
- Funds reported $928M of Bicara Therapeutics stock for Q3 2024.
- 69 funds opened new Bicara Therapeutics positions in Q3 2024 and 0 closed out, a net change of +69 holders.
- The largest Bicara Therapeutics buyer in Q3 2024 was RA Capital Management, an estimated $177M added.
Based on aggregated 13F filings for Q3 2024.